蒽环类化疗药物治疗乳腺癌的毒性与防治工作分析

Analysis of Toxicity and Prevention and Treatment of Anthracycline Chemotherapy Drugs for Breast Cancer

目的分析探究蒽环类化疗药物治疗乳腺癌的毒性,并总结其防治措施。方法从本院2017年1月至2019年1月在本院接受治疗的乳腺癌患者中选择90例作为研究对象,随机分成TC组(TC治疗方案,n=30)、EC组(EC治疗方案,n=30)和EC+右丙亚胺组(EC+右丙亚胺治疗方案,n=30)。借助心肌肌钙蛋白(cTn)方法对蒽环类药物造成的心脏毒性实施监测,期间以乳腺癌患者接受化疗药物治疗之前的心脏彩超作为心肌评价的唯一标准。在此基础上,对比观察三组患者药物治疗后其心脏毒性的发生情况,综合分析EC+右丙亚胺在防治蒽环类药物对心脏毒性的防治效果。结果EC组与EC+右丙亚胺组患者接受药物治疗后的心肌毒性发生情况显著高于TC组(P<0.05),同时,EC+右丙亚胺组患者发生心肌毒性的问题明显优于EC组。结论蒽环类药物在乳腺癌患者临床治疗中的应用会产生一定的心脏毒性,并且右丙亚胺在蒽环类药物心脏毒性防治过程中发挥着积极的作用。

Objective To analyze the toxicity of anthracycline-based chemotherapy drugs in the treatment of breast cancer,and to summarize its prevention and treatment measures.Methods Ninety-eight patients with breast cancer who were treated in our ho spital from January 2017 to January2019 were enrolled in the study.They were randomly divided into TC group(TC treatment plan,n=30)and EC group(EC).Treatment protocol,n=30)and EC+dextromethionine group(EC+dextromethionine treatment regimen,n=30).Cardiac toxicity caused by anthracyclines was monitored by the cardiac troponin(cTn)method,and cardiac color Doppler ultrasound before breast cancer patients received chemotherapy drugs was the sole criterion for myocardial evaluation.On this basis,the occurrence of cardiotoxicity after drug treatment in three groups of patients was compared and comprehensively analyzed.The effect of EC+dextran on the prevention and treatment of anthracyclines on cardiotoxicity was analyzed.Results The incidence of myocardial toxicity in the EC group and the EC+dexilide group was significantly higher than that in the TC group(P<0.05).At the same time,the problem of myocardial toxicity in the EC+dexilamine group was significantly better than that in the EC group.group.Conclu sion The application of anthracyclines in the clinical treatment of breast cancer patients will produce certain cardiotoxicity,and dextropropylamine plays an active role in the prevention and treatment of anthracycline cardiotoxicity.